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Introduction. Adult extracorporeal carbon dioxide removal (ECCO2R) systems and pediatric ECMO 
share the common objectives of having a low blood flow rate and low priming volume while safely 
maintaining sufficient respiratory support. The Hemolung is a highly simplified adult ECCO2R system 
intended for partial respiratory support in adult patients with acute hypercapnic respiratory failure. 
Purpose. The objective of this work was to conduct pre-clinical feasibility studies to determine if a 
highly efficient, active-mixing, adult ECCO2R system can safely be translated to the pediatric population. 
Methods. 14 healthy nonsedated juvenile sheep were used for acute (2 animals) and 7-day chronic 
(12 animals) in-vivo studies and to allow evaluation of treatment safety independently of respiratory 
related injuries. In all evaluations, we hypothesized that gas exchange capabilities of the Hemolung RAS 
in this model would be equivalent to those for the adult configuration performance at similar blood flows 
- minimum CO2 removal of 50 mL/min at a venous partial pressure of CO2 equal to 45 mmHg. Target 
blood flow rates were set to a minimum of 280 mL/min. Swan Ganz catheters were used under general 
anesthesia in two acute studies to evaluate blood gases status in the pulmonary artery. 
Results. The Hemolung RAS was found to have adequate gas exchange and pumping capabilities for 
full respiratory support for the patients weighing 3 - 25 kg. Hemolung device was estimated to provide 
a partial respiratory support for the patients weighing 27 - 34kg. Seven-day animal studies in juvenile 
sheep demonstrated that veno-venous extracorporeal support could be provided safely at low-flows with 
no significant adverse reactions related to device operation. 
Conclusions. These study outcomes suggest the potential use of the Hemolung RAS in a veno-venous 
pediatric configuration to safely provide respiratory support utilizing a significantly less complex system 
than traditional pediatric ECMO. 
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